LENZ Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2025 Annual Meeting of Stockholders held by LENZ Therapeutics, Inc. on June 10, 2025. The Company is an emerging growth company incorporated in Delaware, with its common stock trading on The Nasdaq Stock Market LLC under the symbol "LENZ".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
As of the record date (April 14, 2025), the Company had 27,544,520 shares of common stock outstanding. A total of 17,983,676 shares were represented at the Annual Meeting.
1. Election of Directors
Stockholders elected the following nominees:
| Nominee | Class | Votes For | Votes Withheld | Broker Non-Votes |
|---|---|---|---|---|
| Kimberlee C. Drapkin | III | 12,390,015 | 3,157,989 | 2,435,672 |
| Zach Scheiner | III | 12,714,299 | 2,833,705 | 2,435,672 |
| Frederic Guerard | I | 15,369,962 | 178,042 | 2,435,672 |
| James McCollum | I | 15,397,013 | 150,991 | 2,435,672 |
2. Ratification of Auditors
The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.
| Votes For | Votes Against | Abstentions | Broker Non-Votes |
|---|---|---|---|
| 17,979,770 | 2,698 | 1,208 | — |
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Meeting Date: June 10, 2025.
- Shareholder Participation: Approximately 65.3% of outstanding shares were represented at the meeting.
- Director Tenure: Class III directors (Drapkin, Scheiner) serve until the 2027 annual meeting; Class I directors (Guerard, McCollum) serve until the 2028 annual meeting.
- Auditor: Ernst & Young LLP was ratified with overwhelming support (99.98% of votes cast).
- Financial Data: No financial performance metrics are included in this specific filing.